Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Icosapent Ethyl→

Icosapent Ethyl Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
86227-47-6
Molecular formula
C22H34O2
Molecular weight
330.51 g/mol
Drug class
Ethyl ester of eicosapentaenoic acid (EPA)omega-3 fatty acid lipid-modifying agent
Mechanism of action
Icosapent ethyl is hydrolysed to EPA. EPA may reduce hepatic very-low-density lipoprotein triglyceride synthesis and/or secretion and enhance triglyceride clearance; additional anti-inflammatory and membrane effects may contribute, but the precise cardiovascular risk-reduction mechanism is not fully established.
Indications / reported uses
  • Adjunct to maximally tolerated statin therapy to reduce triglyceride levels in adults with severe hypertriglyceridaemia
  • Adjunct to statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation in eligible adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors

Sources: US DailyMed — VASCEPA (icosapent ethyl) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ethyl ester of eicosapentaenoic acid (EPA); omega-3 fatty acid lipid-modifying agent

Mechanism of action

Icosapent ethyl is hydrolysed to EPA. EPA may reduce hepatic very-low-density lipoprotein triglyceride synthesis and/or secretion and enhance triglyceride clearance; additional anti-inflammatory and membrane effects may contribute, but the precise cardiovascular risk-reduction mechanism is not fully established.

General use cases

  • Adjunct to maximally tolerated statin therapy to reduce triglyceride levels in adults with severe hypertriglyceridaemia
  • Adjunct to statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation in eligible adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Icosapent Ethyl Environmental Risk Assessment (ERA) (the Icosapent Ethyl ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.